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ABSTRACT We report that dendritic cells (DC) are necessary
and potent accessory cells for anti-sheep erythrocyte responses in
both mouse and man. In mice, a small number of DC (0.3-1% of
the culture) restores the response of B/T-lymphocyte mixtures to
that observed in unfractionated spleen. An even lower dose (0.03-
0.1% DC) is needed if the T cells have been primed to antigen.
Responses are both antigen and T cell dependent. Selective de-
pletion of DC from unfractionated spleen with the monoclonal an-
tibody 33D1 and complement ablates the antibody response. In
contrast to DC, purified spleen macrophages are weak or inactive
stimulators. However, when mixed with DC, macrophages can
increase the yield of antibody-secreting cells about 2-fold. In man,
small numbers (0.3-1%) of blood DC stimulate antibody forma-
tion in vitro. Purified human monocytes do not stimulate but in
low doses (1% of the culture) inhibit the antibody response. Like-
wise, selective removal of human monocytes with antibody and
complement enhances or accelerates the development of anti-
body-secreting cells. We conclude that DC are required for the
development of T-dependent antibody responses by mouse and
human lymphocytes in vitro.
Dendritic cells (DC) are specialized stimulators, or accessory
cells, for the immune response (reviewed in refs. 1 and 2). Most
of the work in this and other laboratories has focused on T-lym-
phocyte responses. We have now studied the primary antibody
response to sheep erythrocytes (SRBC). DC prove to be ef-
fective stimulators of antibody formation in both mouse and hu-
man lymphocyte cultures. In contrast, mononuclear phagocytes
are weak or inactive. Human monocytes in small numbers (1%)
inhibit the development of antibody-secreting cells. This may
explain the prior difficulties in initiating human B-cell re-
sponses in vitro.
MATERIALS AND METHODS
Animals. Mice of either sex, 6-10 wk of age, were used. Swiss
mice were from The Rockefeller University, whereas (A X B6)
F1, (DBA/2 X BALB/c) F1, and (BALB/c X C57BL/6) F1 were
from The Trudeau Institute (Saranac Lake, NY).
Antigen. SRBC and ox erythrocytes (Colorado Serum, Den-
ver, CO) were stored in Alsever's at 4°C and used within 2 wk
of shipment.
Antibodies. 33D1 (3, 4) and B21-2 (5) are rat monoclonal an-
tibodies specific for mouse DC and I-Abd antigens, respec-
tively. TIB-99 is a monoclonal anti-mouse thy-1.2 (6) obtained
from the American Type Culture Collection (Rockville, MD).
3C10, BA-1, and Leu-1 are mouse monoclonal antibodies that
react with human macrophages (MO), B cells, and T cells, re-
spectively, but not with DC (7).
Table 1. DC stimulate the development of antibody-forming cells
PFC per culture
Exp. Exp. Exp. Exp. Exp. Exp.
Cells 1 2 3A 3B 4A 4B
Spleen 518 288 410 1,847 491 3,026
G-10
- DC 13 3 7 34 0 91
+ 0.01%DC - - 47 703 13 742
+ 0.03% DC - 87 1,621 67 2,119
+ 0.10% DC - 162 173 2,459 91 2,567
+ 0.15% DC 60 - - - - -
+ 0.30%DC - 385 263 3,644 317 3,309
+ 0.50% DC 720 - - - -
+ 1.0% DC - 792 777 4,165 472 3,015
+ 1.5% DC 1,653 - - - -
+ 3.0% DC - - 813 4,743 504 2,233
Unfractionated spleen cells or Sephadex G-10 nonadherent spleen cells
(primarily B and T lymphocytes) (5 x 106) supplemented with varying
doses of DC were cultured for 4 days with 5 x 106 SRBC as antigen.
Values given are direct PFC; the standard deviation ofthe plaque assay
was <15%. The PFC response in the absence of SRBC ranged from 3-
136. In experiments 3 and 4, the DC were tested for accessory function
on unprimed spleen (part A) or spleen from mice primed with 4 x 106
SRBC intraperitoneally 4 days previously (part B), a dose that primes
T cells primarily (15).
Cell Preparation. Spleen suspensions were prepared as de-
scribed, including passage over Sephadex G-10 (Pharmacia) to
yield accessory cell-dependent B/T lymphocyte mixtures (8).
The accessory cells used to reconstitute antibody responses were
purified DC (80-90% pure; ref. 9) or MO-DC adherent cell
mixtures (4). These adherent cells and unfractionated spleen
were depleted of DC with 33D1 antibody and rabbit comple-
ment (C; ref. 4). Because the level of DC in spleen is so low
(<1%), we monitored the efficacy of the depletion procedure
by microscopic observation of the spleen adherent component
(2, 4). 33D1 and C reduced the frequency of DC from 10-40%
of adherent cells to 0-3%.
Human peripheral blood mononuclear cells and plastic-ad-
herent cells were prepared as described (7, 10). Enriched pop-
ulations (>97% pure) of monocytes were plastic-adherent cells
that remained attached after overnight culture (7, 10). DC (30-
70% pure by cytologic criteria) were obtained from adherent
cells that had detached from the plastic surface after overnight
culture and had been treated with monoclonal anti-monocyte
and lymphocyte antibodies to enrich for DC (7). Selective de-
pletion of monocytes from blood mononuclear cells was done
with 3C10 antibody and C. This killed >95% of monocytes, as
judged by nonspecific esterase staining and by cytology (7), and
Abbreviations: DC, dendritic cell(s); SRBC, sheep erythrocyte(s); PFC,
plaque-forming cell(s); C, complement; MO, macrophages/monocytes.
6041
The publication costs of this article were defrayed in part by page charge
payment. This article must therefore be hereby marked "advertise-




















Proc. Natl. Acad. Sci. USA 80 (1983)
Table 2. Antibody responses induced by DC are antigen
dependent and specific
Number of anti-sheep or anti-ox PFC in
Erythrocytes G-10 nonadherent G-10 nonadherent
used as responders responders + 0.5% DC
antigen Anti-sheep Anti-ox Anti-sheep Anti-ox
None 25/8 38/10 61/10 75/19
Sheep 20/4 29/15 1,553/31 298/20
Ox 19/10 43/12 584/31 2,261/80
Sephadex G-10 nonadherent spleen cells were stimulated with SRBC
or ox erythrocytes in the absence (left) or presence (right) of 0.5% pu-
rified DC. At day 4, PFC responses were measured in both SRBC and
ox erythrocyte plaque assays. Data are means ± SD of triplicate cul-
tures. The degree of sheep and ox crossreactivity in vitro is similar to
that observed with immunization in situ (16).
the populations remained monocyte-depleted for 9 days in cul-
ture. Human B/T lymphocyte mixtures, which required ac-
cessory cells to generate antibody responses, were obtained by
three techniques: sedimentation in self-generated Percoll
(Pharmacia) gradients (11); passage over Sephadex G-10 col-
umns as above (8); and two adherent cell depletions on plastic
(10).
Culture Conditions. For mouse cultures we used RPMI 1640
(GIBCO) with 10% heat-inactivated fetal calf serum (HiClone,
Sterile Systems, Logan, UT), 50 ,uM 2-mercaptoethanol, and
20 ,ug of gentamycin sulfate per ml. Graded doses of irradiated
accessory cells were added to 5 X 106 responders and cultured
for 4-5 days with or without 5 X 106 SRBC in 16-mm wells and
a total volume of 1.2 ml.
For human cells we used RPMI 1640 with 20% fetal serum,
gentamycin, 2-mercaptoethanol, 25 mM Hepes, and 2 mM L-
glutamine. Although not shown in Results, isologous plasma
[15% (vol/vol)] could be used instead of fetal calf serum for DC-
mediated primary anti-SRBC responses. Cells (2.5 x 106) were
cultured in 16-mm wells for 6-12 days with or without an equal
number of SRBC in a total volume of 1.2 ml. After 5 days, the
cultures were fed daily with 50 ,lI of culture medium.
Plaque-Forming Cells (PFC). Direct or IgM antibody-se-
creting cells were counted with a plaque assay in agarose gel as
described (8).
RESULTS
DC Induce Plaque-Forming Responses in Nonadherent
Mouse Spleen Cells. Spleen cells passed over Sephadex G-10
require accessory cells for the development of antibody re-
Table 3. Selective elimination of DC with 33D1 monoclonal
antibody and C ablates antibody-forming responses
by mouse spleen
PFC response of spleen treated with
No Ab 33D1
Exp. No C C heated C fresh No C C heated C fresh
1 - - 1,390 - - 17
2 - - 2,483 - 37
3 714 - 561 - 123
4 518 - 429 - - 19
5 203 128 212 164 168 23
6 1,094 894 1,110 1,372 1,230 10
Spleen cells were exposed to no antibody (Ab) or 33D1 anti-DC Ab
with either no C, heated (56°C, 1/2 hr) C, or active C. The cells were washed
and cultured for 4 days with SRBC as antigen. Values shown are PFC
per culture. Standard deviations were all <15%. PFC responses in the
absence ofSRBC were <10% ofthose listed. In experiment 3, the 33D1/
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FIG. 1. DC reconstitute the response of 33Dl/C-treated spleen cells.
Graded doses of DC were added back to whole spleen that had been
treated with 33D1 monoclonal antibody and C. PFC were measured with
(-*) or without --) SRBC antigenic stimulation. Control PFC
responses were 1,048 ± 190 (no antibody, no C) and 839 ± 203 (C only).
sponses (8, 12-14). Our first experiments showed that purified
DC provided the accessory cell requirement for the generation
of PFC (Table 1). As few as 0.3-1% DC induced responses
comparable to or greater than that of whole spleen. If the T
cells were primed with a low dose of SRBC in situ, the sec-
ondary response needed only 0.03-0.1% DC (Table 1, exper-
iments 3 and 4).
The DC-stimulated PFC response was antigen dependent
(Table 1) and specific (Table 2), as demonstrated by comparing
the responses to SRBC and ox erythrocytes. In 20 consecutive
experiments (not shown), DC did not stimulate an anti-SRBC
antibody response if T cells had been depleted from the Seph-
adex G-10 nonadherent population with anti-thy-i monoclonal
antibody and C. We conclude that DC are potent stimulators
of antigen- and T-cell-dependent PFC responses.
Selective Removal of DC Ablates PFC Responses in Un-
fractionated Spleen. The need for DC was verified by killing
these cells with a specific monoclonal antibody (33D1; refs. 3
and 4) and C. Selective elimination of DC with 33D1 and C
ablated the antibody-forming capacity of mouse spleen (Table
Table 4. Selective elimination of DC with 33D1 monoclonal
antibody and C ablates the accessory function of spleen
adherent cells
PFC in cultures of
Spleen Sephadex G-10 nonadherent spleen
Exp. * -* No Ab, No Ct C onlyt 33D1, Ct
1 395 11 408 400 13
2 1,413 0 943 1,313 17
3 845 27 - 210 15
4 760 12 - 720 7
5 786 0 150 160 0
6 561 12 - 440 188
7 1,317 56 1,179 1,413 259
8 410 7 323 227 13
PFC responses to SRBC were measured after 4 days of culture. Re-
sponding cells (5 x 106 per culture) were whole spleen or Sephadex G-
10 nonadherent spleen (B andT lymphocytes) reconstituted with spleen
adherent cells (3-10 x 104 per culture) that had been treated with no
antibody (Ab) or 33D1 anti-DC and C. Responses in the absence of SRBC
were 0-123 PFC. The spleen adherent cells were not irradiated, but in
experiments 3 and 4, irradiated cells were compared to unirradiated
cells and gave similar data. In experiments 2 and 8, adherent cells treated
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FIG. 2. Purified spleen MO are not active accessory cells for the PFC
response. Cultured spleen adherent cells (SAC; 80% MO) were treated
with no antibody and C (o) or 33D1 anti-DC and C (.), irradiated, and
tested as accessory cells in PFC responses. Purified DC (A) were also
studied. The percentage of Ia-bearing M4 in the spleen adherent pop-
ulation was 35%, as determined by indirect immunofluorescence with
an Fab fragment of the monoclonal antibody B21-2. The control PFC
response for whole spleen is shown at the top left.
3). The function of these 33D1/C-treated spleen cells was re-
constituted with small numbers of DC enriched by a technique
not requiring the 33D1 antibody (Fig. 1).
The Effects of Spleen MO on Murine PFC Responses. The
role of MO in PFC development was studied with 33D1- and
C-treated spleen adherent cells. Most of the remaining cells
were M4 that expressed Fc receptors, MO-restricted surface
antigens, and phagocytic capacity (2-4). These MO were in-
active as accessory cells (Table 4). Suspensions of adherent cells
obtained after overnight culture were also tested. These mix-
tures of MO and DC were <20% as active as enriched DC (Fig.
2). Selective elimination of DC with 33D1 and C again re-
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FIG. 4. DC stimulate and monocytes, inhibit the human primary
PFC response. Plastic nonadherent,-peripheral blood mononuclear cells
were passed over Sephadex G-10 columns to provide accessory cell-de-
pendent mixtures of human B and T lymphocytes. Cells (2.5 x 106)-were
cultured in 16-mm wells in the presence of graded doses of accessory
cells: a, purified monocytes obtained from 1-day cultures of adherent
cells that remained attached to plastic; o, adherent cells that were re-
leased from -plastic after 1 day of culture (mixtures of monocytes, lym-
phocytes, and DG); 9, enriched populations -of DC (>70% by cytologic
criteria) that were depleted of monocytes, and lymphocytes with mono-
clonal antibodies and C; A, a fixed number of DC (0.3%) supplemented
with the doses of monocytes shown on the abscissa. PFC responses to
SRBC were measured at 7 and 9 days of culture. No PFC were detected
in the absence of SRBC.
To test for a possible synergism between MO and DC, we
added back-graded doses of purified DC to spleen MO that had
been treated with 33D I and C. The DC-mediated response was
increased about 2-fold when small numbers of MO (0.5-1%)
were present (Fig. 3).
Accessory Cell Requirements for Human PFC Responses.
Accessory cell-dependent, human blood B and T cells were
prepared in three ways (see Materials arnd Methods). As in mice,
small numbers (0.3-1%) of DC induced an anti-SRBC PFC re-
sponse, whereas enriched populations of MO did not (Fig. 4,
Table 5). However, very low levels (0.1-0.3%) of monocytes
enhanced the DC-mediated response, whereas -higher levels
0 .15 0.3 0.6 1.2 2.4 0 .03 .10 .30 1.0 3.0
Percent dendritic cells added to culture
FIG. 3. MO can enhance a DC-mediated PFC response. Sephadex G-10 nonadherent spleen was supplemented with graded doses of DC
(v--) or graded doses of DC and a constant number ofMO (0*- ; spleen adherent cells treated with 33D1 antibody and C to eliminate DC).
Other data from these experiments are given in Table 4, experiments 1 and 2. PFC responses in the absence of antigen were <90 PFC per culture.
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Table 5. DC stimulate and monocytes inhibit the primary anti-SRBC response of human
blood lymphocytes
PFC response (with/without SRBC) stimulated by
Monocyte-
Day No DC-enriched enriched
of accessory populations populations DC + 1%
Exp. assay cells 0.3% 1.0% 1.0% 3.0% monocytes
1 6 0/0 205/0 440/0 40/0 32/0 NT
2 8 0/3 78/0 130/0 0/3 3/0 30/3
3 8 0/0 33/0 93/0 NT NT NT
4 7 0/0 67/0 150/0 0/0 3/0 11/0
5 7 0/0 103/0 215/0 5/0 9/0 61/0
5 9 0/0 205/0 289/0 0/0 0/0 89/0
Accessory cell-dependent, human peripheral blood lymphocytes were prepared by adherence to plastic
(experiment 1), sedimentation in dense Percoll (experiments 2 and 3), or passage over Sephadex G-10 col-
umns (experiments 4 and 5). These B/T lymphocyte mixtures were cultured in the presence or absence
of SRBC and no accessory cells, DC-enriched populations, monocyte-enriched populations (see text), or
mixtures ofDC (0.3% in experiments 2 and- 5; 1% in experiment 4) and 1% monocytes. Direct or IgM PFC
were measured on the indicated days. NT, not tested.
(1%) reproducibly inhibited PFC development (Fig. 4, Table
5).
The selective removal of monocytes enhanced PFC devel-
opment in peripheral blood mononuclear cells; >95% of blood
monocytes could be removed with the 3C10 monoclonal anti-
body and C as described (7). Monocyte depletion had two con-
sequences that depended on the cell donor. One result was that
the removal of monocytes allowed a PFC response to occur (e.g.,
Fig. 5, experiment 1). This finding was reproduced twice in this
donor and with one other donor. In a third donor (Fig. 5, ex-
periment 2), monocytes repeatedly delayed rather than blocked
PFC development.
DISCUSSION
The antibody response to SRBC (17) was one of the first sys-
tems in which primary immune responses were generated in
culture. In addition to lymphocytes, successful immunization
required accessory cells, selected by adherence to glass or to
plastic (18-22). DC were discovered in studies aimed at char-
acterizing the active adherent cell (23). DC were distinguished
and separated from. other adherent cells, principally.M , and
were shown to be active stimulators of several T-cell responses
(reviewed in refs. 1 and.2). We have returned to the primary
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thymus-dependent B-cell development. Specifically, small
numbers (<1% of the culture) of purified DC are sufficient for
active PFC responses in both mouse and man (Tables 1 and 5).
Selective elimination of mouse DC with 33D1 monoclonal an-
tibody and C removes.both the antibody response of whole spleen
(Table 3 and Fig. 1) and the accessory function of heteroge-
neous adherent populations (Table 4 and Fig. 2).
The effect of DC on antigen-specific responses most likely
involves helper T lymphocytes that are induced to grow or func-
tion (or both) in response to DC and antigen. Some of the helper
effects may not be antigen dependent, because DC are strong
stimulators of the syngeneic mixed leukocyte reaction, which
in turn results in the production of helper factors (24, 25). It is
also possible that DC can interact directly with B cells. For ex-
ample, it is known that DC and T cells can physically aggregate
with developing B cells in vitro (ref. 26; unpublished data).
However, we still do not know if DC and B cells will cluster
independently of T lymphocytes.
The contribution of MO to antibody responses is complex
and entails three findings. First, enriched populations of mouse
spleen MO and human blood monocytes by themselves are weak
or inactive accessory cells for anti-SRBC responses (Tables 4
and 5; Figs. 2 and 4). Many, if not most, of the M0 in our-test
populations expressed Ta antigens. Therefore, we could not
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FIG. 5. Depletion of monocytes enhances human PFC responses. Blood mononuclear cells from two donors (experiments 1 and 2) were exposed
to3C10 anti-monocyte antibody andC (v) to eliminate >95% ofthe monocytes (asjudged by nonspecific esterase staining). Controls (e) were exposed
to C only (or in other experiments to antibody alone). PFC responses to SRBC were measured on successive days in cultures of 2.5 x 10q cells. Viable
cell recoveries (70% of the starting dose) were similar in all cultures. No PFC developed in, the absence of SRBC in one donor (A, experiment 1),
but a few were detected in the other (A, experiment 2).
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MO are essential for antibody responses. Instead, the active Ia+
cell under our experimental conditions is the DC.
The second point is that a very small number of MO (<1%
of the culture) enhances the stimulation by DC (Figs. 3 and 4).
This increase can even be mediated by 1a- MO (12) and perhaps
by other la- cells, such as cultured fibroblasts (27, 28). Syn-
ergism may involve the production of interleukin 1 (29) or ad-
ditional "trophic" effects on cell viability (30).
The third finding is that MO can inhibit the PFC response.
Inhibition is known to require relatively high numbers in mice
(2.5% of the culture; e.g., see refs. 22 and 30), but we find that
inhibition occurs at very low doses in man (1%; Table 5 and Fig.
4). The realization that monocytes inhibit and DC stimulate an-
tibody formation has led us to test the effect of selective mono-
cyte depletion on human anti-SRBC responses. Responses are
enhanced or accelerated after the elimination of most mono-
cytes with a specific monoclonal antibody and C (Fig. 5). The
human PFC response (100-700 PFC at days 6-8) seems com-
parable to the murine system, because the number of B cells
that are cultured is about 10% of that used in murine systems.
Although SRBC is the only antigen we have studied, our data
indicate that the development of human antibody responses
can best be achieved by removing rather than adding mono-
cytes, as has been assumed (31-33). This change in approach
toward in vitro immunization hopefully will permit the study
of primary B-cell responses in clinical samples and aid in the
development of B-cell hybridomas that secrete high levels of
human monoclonal antibodies.
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